Mendus AB (publ) (IMMU) Earnings Call Transcripts

Mendus AB (publ)'s Latest Earnings Call - Q1 FY2026

In Q1 2026, Mendus AB reported a cash position of SEK 74 million, up from SEK 64 million in Q4 2025, driven by cost savings and a SEK 30 million loan tranche. The company is actively recruiting for its AMLM22-CADENCE trial, with 16 out of 20 patients enrolled, and has initiated the VITAL-CML trial for chronic myeloid leukemia (CML). Management emphasized the importance of positioning their product, vididencel, in the evolving AML landscape, particularly as they aim for a broader patient base and improved treatment outcomes.

Reported metrics

Guidance from management

Management reiterated confidence in their cash runway, stating it will allow them to reach key milestones for their clinical programs by year-end. They aim to initiate the Phase II trial in CML before the end of 2026, contingent on safety data from the ongoing Phase I trial.

What management said

Yes. And the financial summary for the quarter was that the costs in the quarter were approximately SEK 20 million, which is SEK 10 million lower than the same period last year. And this is the effect of the reorganization and the cost savings we did in the second half of last year. And during the quarter, we have also executed on the first tranche for the Fenja loan, which added SEK 30 million to the cash position. ...

Exactly. Well, that's when we will need to do the analysis. So around that time, it will not take too long, but one way or the other, of course, we have to first reach 20 patients, then open the samples, et cetera, and do the analysis. So most important is first that we get to the 20 patients and then we do the analysis, and we will report shortly afterwards.

What analysts pressed on

Analysts expressed concerns regarding the recruitment speed for the CADENCE trial, noting competitive pressures from other trials in the AML landscape. There were also inquiries about the characteristics of patients being enrolled in the CML study and the definition of suboptimal responses.

Main topics on the call

• Clinical Trial Progress — Mendus is currently recruiting for the AMLM22-CADENCE trial, with 16 patients enrolled and a target of 20 by mid-2026. CEO Erik Manting stated, "We are now at 16 patients recruited, and we're still aiming for 20 patients...
• Cost Management — The company reported Q1 costs of approximately SEK 20 million, which is SEK 10 million lower than the same period last year, attributed to reorganization and cost-saving measures. CFO Lotta Ferm noted, "this is the effec...
• CML Program Initiation — Mendus has commenced the VITAL-CML trial, targeting patients with suboptimal responses to TKIs. This trial aims to improve treatment-free remission rates, with the first patients already recruited in Bergen, Norway.
• Focus Shift to Myeloid Blood Cancers — Management indicated a strategic pivot towards myeloid blood cancers, stating that the focus will now be on this area due to its competitive landscape. Erik Manting mentioned, "the myeloid blood cancers from now on will ...

Read the full Mendus AB (publ) transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 24 Mendus AB (publ) earnings call transcripts on record, spanning September 30, 2020 to August 20, 2026. Based on this history, Mendus AB (publ) reports quarterly. The most recent call on file is dated August 20, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

IMMU

Exchange

OM

Country

SE

Sector

Health Care

Industry

Biotechnology

Calls on record

24

First call

September 30, 2020

Most recent

August 20, 2026

Reporting cadence

quarterly